NEW YORK, June 5 – DeCode Genetics said Tuesday it has appointed Michael Young to the newly created position of vice president of business development.
In the new role, Young will be in charge of building the company’s corporate alliances for its research and product development programs.
Young, 49, previously worked at Genzyme Transgenics, where he was most recently vice president of commercial development. He has also worked as the head of business development at PerSeptive BioSystems and at Millipore.
"His experience, track record, and detailed knowledge of the industry in the US, Europe and Asia offer ideal leadership for our expanding business development efforts,” Kari Stefansson, DeCode’s CEO, said in a statement. “I believe he will play a key role in maximizing the worldwide opportunities for DeCode's business as we continue to turn our research into products on the market."
DeCode of Reykjavik, Iceland is currently working to expand its research programs and product offerings in gene discovery, pharmacogenomics, drug and diagnostic development, as well as database and bioinformatics products and services.